image description

Press Releases

Press Releases

January 9, 2020
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P.
January 9, 2020
Revance Provides Corporate Update and Anticipated Milestones for 2020
NEWARK, Calif. --(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update and shared anticipated
December 4, 2019
Revance Announces Pricing of Public Offering of Common Stock
NEWARK, Calif. --(BUSINESS WIRE)--Dec. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public
December 3, 2019
Revance Announces Proposed Public Offering of Common Stock
NEWARK, Calif. ,--(BUSINESS WIRE)--Dec. 3, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public
November 12, 2019
Revance to Participate in the Stifel 2019 Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,
November 6, 2019
Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference
NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare
Displaying 1 - 10 of 191